Scholarlink

Purpose <p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the second leading indication for liver transplant in the United States, but the prevalence is unevenly distributed across ethnic groups with 22.3% of Hispanic patients affected. This study aimed to assess racial and ethnic diversity among MASLD clinical trials.</p> Methods <p>We performed a meta-analysis of 91 randomized controlled trials (RCTs) of MASLD therapies in the US and Canada, and multinational RCTS involving the US from 2005 to 2024.</p> Results <p>78 studies (85.7%) reported racial data and only 56 (61.5%) included ethnicity data. Meta-analysis revealed a pooled prevalence of 78.8% (95% CI 72.9 – 84.6, I<sup>2</sup> = 97.0%) in White patients, 6.2% (95% CI 4.1 – 8.3, I<sup>2</sup> = 94.1%) in Asian patients, 2.5% (95% CI 1.6 – 3.5, I<sup>2</sup> = 70.2%) in Black patients, and 31.7% (95% CI 26.8—36.6, I<sup>2</sup> = 96.2%) in Hispanic patients. This prevalence was higher than the reported national Hispanic prevalence, and Hispanic enrollment also increased over time from 20.3% (2009 – 2014), 30.8% (2015–2019), to 40.0% (2020–2024).</p> Conclusion <p>Our results show that compared to previous efforts, clinical trials are increasingly including Hispanic patients, yet they still need to increase inclusion of ethnicity data. Since MASLD disproportionately affects Hispanic patients, it is imperative that clinical trials make a targeted effort to diversify patient recruitment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recruitment of Minority Patients in Metabolic Dysfunction-Associated Steatotic Liver Disease Clinical Trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月6日

查看全文
  • Sarah E. Park,
  • Yael Wollstein,
  • Alan L. Hutchison,
  • Sonali Paul

摘要

Purpose

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the second leading indication for liver transplant in the United States, but the prevalence is unevenly distributed across ethnic groups with 22.3% of Hispanic patients affected. This study aimed to assess racial and ethnic diversity among MASLD clinical trials.

Methods

We performed a meta-analysis of 91 randomized controlled trials (RCTs) of MASLD therapies in the US and Canada, and multinational RCTS involving the US from 2005 to 2024.

Results

78 studies (85.7%) reported racial data and only 56 (61.5%) included ethnicity data. Meta-analysis revealed a pooled prevalence of 78.8% (95% CI 72.9 – 84.6, I2 = 97.0%) in White patients, 6.2% (95% CI 4.1 – 8.3, I2 = 94.1%) in Asian patients, 2.5% (95% CI 1.6 – 3.5, I2 = 70.2%) in Black patients, and 31.7% (95% CI 26.8—36.6, I2 = 96.2%) in Hispanic patients. This prevalence was higher than the reported national Hispanic prevalence, and Hispanic enrollment also increased over time from 20.3% (2009 – 2014), 30.8% (2015–2019), to 40.0% (2020–2024).

Conclusion

Our results show that compared to previous efforts, clinical trials are increasingly including Hispanic patients, yet they still need to increase inclusion of ethnicity data. Since MASLD disproportionately affects Hispanic patients, it is imperative that clinical trials make a targeted effort to diversify patient recruitment.